The
placenta is pivotal for fetal development and maternal–fetal
transfer of many substances, including per- and polyfluoroalkyl substances
(PFASs). However, the intraplacental distribution of PFASs and their
effects on placental vascular function remain unclear. In this study,
302 tetrads of matched subchorionic placenta (fetal-side), parabasal
placenta (maternal-side), cord serum, and maternal serum samples were
collected from Guangzhou, China. Eighteen emerging and legacy PFASs
and five placental vascular biomarkers were measured. Results showed
that higher levels of perfluorooctanoic (PFOA), perfluorooctane sulfonic
acid (PFOS), and chlorinated polyfluorinated ether sulfonic acids
(Cl-PFESAs) were detected in subchorionic placenta compared to parabasal
placenta. There were significant associations of PFASs in the subchorionic
placenta, but not in the serum, with placental vascular biomarkers
(up to 32.5%) and lower birth size. Birth weight was negatively associated
with PFOA (β: −103.8, 95% CI: −186.3 and −21.32)
and 6:2 Cl-PFESA (β: −80.04, 95% CI: −139.5 and
−20.61), primarily in subchorionic placenta. Mediation effects
of altered placental angiopoietin-2 and vascular endothelial growth
factor receptor-2 were evidenced on associations of adverse birth
outcomes with intraplacental PFOS and 8:2 Cl-PFESA, explaining 9.5%–32.5%
of the total effect. To the best of our knowledge, this study is the
first to report on differential intraplacental distribution of PFASs
and placental vascular effects mediating adverse birth outcomes and
provides novel insights into the placental plate-specific measurement
in PFAS-associated health risk assessment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.